The upcoming quarter’s "xbi stock price forecast" is underpinned by expectations of positive trial readouts, which historically trigger upward moves in biotech ETFs. Tesla is emerging from a massive long-term base structure, which suggests that the previous all-time highs are likely to be a magnet into 2025. With these factors in play, Tsai rates ANRO a Buy with a $17 price target, implying a robust 507% upside from current levels. (To watch Tsai’s track record, click here ) The latest "xbi stock price forecast" points to cautious optimism, with analysts projecting a potential target of $92–$96 over the next quarter, driven by robust biotech sector earnings and steady inflows from institutional investors.
